argenx (NASDAQ:ARGX)‘s stock had its “buy” rating reissued by investment analysts at Stifel Nicolaus in a research note issued on Thursday.
A number of other equities research analysts have also issued reports on ARGX. Evercore ISI assumed coverage on shares of argenx in a report on Monday, October 15th. They set an “outperform” rating and a $110.00 target price for the company. SunTrust Banks boosted their price target on shares of argenx to $132.00 and gave the company an “in-line” rating in a research report on Tuesday, September 18th. Piper Jaffray Companies reissued an “overweight” rating and set a $154.00 price target on shares of argenx in a research report on Monday, September 17th. JMP Securities boosted their price target on shares of argenx to $150.00 and gave the company an “outperform” rating in a research report on Monday, September 17th. Finally, Wedbush boosted their price target on shares of argenx from $114.00 to $121.00 and gave the company a “positive” rating in a research report on Tuesday, September 18th. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. argenx currently has a consensus rating of “Buy” and a consensus price target of $130.50.
Shares of argenx stock traded up $12.58 during trading hours on Thursday, reaching $92.59. 20,436 shares of the company’s stock were exchanged, compared to its average volume of 241,023. argenx has a 1 year low of $22.21 and a 1 year high of $103.00. The firm has a market capitalization of $2.41 billion, a price-to-earnings ratio of -65.06 and a beta of 2.38.
argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.
Featured Story: What is Considered a Good Return on Equity (ROE)?
Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.